欧洲人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型（颗粒佐剂、乳液佐剂、组合佐剂及其他）、应用（流感、肝炎、人乳头瘤病毒 (HPV) 及其他）和最终用户（制药和生物技术公司、CMO 和 CRO 及其他）划分
个性化疫苗上升趋势推动欧洲人用疫苗佐剂市场发展
精准或个性化疫苗是欧洲人用疫苗佐剂市场的一个增长趋势。这些疫苗针对患者疾病的特定遗传或分子特征，有助于生产针对每位患者独特免疫反应量身定制的疫苗。该技术可以潜在地提高疫苗接种的有效性和安全性，从而引起人们对用于治疗癌症、传染病和自身免疫性疾病等疾病的个性化疫苗的兴趣增加。
生产个性化疫苗需要能够增强这些定制疫苗免疫反应的佐剂。佐剂对于刺激免疫系统对疫苗特定抗原产生有针对性的强大反应至关重要。因此，对能够有效增强个性化疫苗免疫反应的佐剂的需求日益增加。近年来，人们非常重视研发工作，以识别和创造能够有效增加个性化疫苗免疫反应的佐剂。例如，2022 年 12 月，Moderna 和 Merck 宣布推出 mRNA-4157/V940，一种研究性个性化 mRNA 癌症疫苗，与 KEYTRUDA(R)（派姆单抗）联合使用。与单独使用 KEYTRUDA 相比，使用 mRNA-4157/V940 与 KEYTRUDA 联合进行辅助治疗可将复发或死亡风险降低 44%。监管机构和医疗保健组织认识到个性化疫苗在改善公共卫生结果方面的潜力。例如，2023 年 1 月，BioNTech 与英国政府签署了一份影响深远的谅解备忘录 (MoU)，旨在到 2030 年为多达 10,000 名患者提供个性化的 mRNA 癌症免疫疗法。这增加了对该领域研发计划的资金投入，并采取措施加快个性化疫苗和佐剂的监管途径。因此，有效改善个性化疫苗免疫反应的佐剂正在不断开发中，从而提高疫苗的有效性和安全性。这一趋势推动了欧洲人用疫苗佐剂市场的大量创新和投资。
欧洲人用疫苗佐剂市场概览
德国是欧洲乃至全球最大的医药市场之一。据德国贸易与投资署 (GTAI) 称，它是欧盟最大的制药生产基地，拥有约 600 家制药公司。根据 GTAI 的数据，2022 年德国的药品产量达到约 618 亿美元（约合 565 亿美元）。此外，该国在生物制药生产方面排名第二，仅次于美国，这归功于良好的工业基础设施、持续增长的本地化学工业以及高素质的劳动力。据同一消息来源称，2021 年德国制药行业在研发方面投资了近 95 亿美元（约合 88 亿美元），高于其他任何行业的研发投资额。德国的医疗保健行业服务于欧洲最大的人口，是一个极具吸引力的市场，具有巨大的增长机会。预期寿命水平的稳步提高导致慢性病和与年龄相关的疾病增加。传染病流行率的上升预计将刺激对疫苗的需求。例如，根据 ICO/IARC 信息中心 2023 年关于 HPV 和癌症的报告，德国有 3660 万 15 岁及以上的女性面临罹患 HPV 相关宫颈癌的风险。此外，德国的肝炎患病率很高。由于传染病的流行，人们的健康意识增强，进一步增加了消费者对药物、疫苗和疗法的需求。因此，随着制药公司药物研发领域的蓬勃发展以及传染病的流行率不断上升，德国对人用疫苗佐剂的需求正在迅速增长。
欧洲人用疫苗佐剂市场收入及预测至 2030 年（百万美元）
欧洲人用疫苗佐剂市场细分
欧洲人用疫苗佐剂市场分为类型、应用、最终用户和国家。
根据类型，欧洲人用疫苗佐剂市场细分为颗粒佐剂、乳剂佐剂、组合佐剂和其他。颗粒佐剂部分在 2022 年占据最大市场份额。
在应用方面，欧洲人用疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 等。流感部分在 2022 年占据最大市场份额。
按最终用户划分，欧洲人用疫苗佐剂市场细分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司部分在 2022 年占据最大市场份额。
按国家/地区划分，欧洲人用疫苗佐剂市场细分为德国、英国、法国、意大利、西班牙和欧洲其他地区。 2022 年，德国占据了欧洲人类疫苗佐剂市场的主导份额。
Creative Biolabs Inc、Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是欧洲人类疫苗佐剂市场的一些领先公司。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Human Vaccine Adjuvants Market - Key Market Dynamics
4.1 Europe Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market - Europe Market Analysis
5.1 Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Europe Human Vaccine Adjuvants Market Forecast Analysis
6. Europe Human Vaccine Adjuvants Market Analysis - by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Human Vaccine Adjuvants Market Analysis - by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human Papilloma Virus (HPV)
7.3.1 Overview
7.3.2 Human Papilloma Virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Human Vaccine Adjuvants Market Analysis - by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Human Vaccine Adjuvants Market - Country Analysis
9.1 Europe
9.1.1 Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Germany Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 Germany Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 Germany Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 UK Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 UK Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 UK Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 France Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 France Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 France Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.4 Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Italy Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.4.2 Italy Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.4.3 Italy Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.5 Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.5.1 Spain Vaccine Adjuvants Market Breakdown, by Type
9.1.1.5.2 Spain Vaccine Adjuvants Market Breakdown, by Application
9.1.1.5.3 Spain Vaccine Adjuvants Market Breakdown, by End User
9.1.1.6 Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.6.1 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.6.2 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.6.3 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Dynavax Technologies Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 CSL Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Seppic SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 SPI Pharma Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Croda International Plc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Novavax Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Phibro Animal Health Corp
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Creative Biolabs Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. Europe Human Vaccine Adjuvants Market Segmentation
Table 2. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 19. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 20. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 21. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 23. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market
List of Figures
Figure 1. Europe Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Europe Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
1. Creative Biolabs Inc
2. Croda International Plc
3. CSL Ltd
4. Dynavax Technologies Corp
5. Novartis AG
6. Novavax Inc
7. Phibro Animal Health Corp
8. Seppic SA
9. SPI Pharma Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe human vaccine adjuvants market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe human vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.